Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina

January 16, 2020

Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina.

With these approvals, VYZULTA is now approved for commercialization in a total of five countries and territories. VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA as well as up to $150 million in potential future milestones.

Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC).

← Back to blog page